Breast Cancer
CE/CME accredited
touchIN CONVERSATION
A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Close
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
Videos
Learning Objectives & Overview
Claim Credit
Toolkit
Notes
This activity is CE/CME accredited
To obtain the credit(s) from this activity, please complete this post-activity test.
Claim Credit
You may also be interested in...
JOURNALS
Quality and Reliability of Spanish-language YouTube Videos on Breast Cancer
GO TO ARTICLE
touchPANEL DISCUSSION
New and emerging agents in HER2-negative metastatic breast cancer: Implications for current and future practice
This activity is CE/CME accredited
LAUNCH ACTIVITY
touchCONGRESS
Utilizing the latest data from SABCS 2020 to optimize the management of patients with HR+/HER2- breast cancer
This activity is CE/CME accredited
LAUNCH ACTIVITY
CONFERENCE HUB
Eleni Andreopoulou, ASCO 2019 – Immunotherapy in breast cancer (Part 2)
GO TO HUB
CONFERENCE HUB
Eleni Andreopoulou, ASCO 2018 – Improving quality of life in patients with breast cancer
GO TO HUB
JOURNALS
Foreword – Oncology & Hematology Review (US), 2013;9(1):5
GO TO ARTICLE
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGY
Claim Credit
touchIN CONVERSATION
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
You may also be interested in...
CONFERENCE HUB
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, ESMO 2023
GO TO HUB
CONFERENCE HUB
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
GO TO HUB
touchIN CONVERSATION
Navigating the evolving treatment landscape in mTNBC: What are the key considerations for clinical practice today?
This activity is CE/CME accredited
LAUNCH ACTIVITY
touchPANEL DISCUSSION
Expanding options for HER2 advanced breast cancer: Taking trial data to the clinic
This activity is CE/CME accredited
LAUNCH ACTIVITY
JOURNALS
Current State of Fertility Preservation in Cancer Patients—What is Established and What is Still Controversial?
GO TO ARTICLE
JOURNALS
Temporary Ovarian Suppression in the Prevention of Chemotherapy-induced Premature Menopause in Early-stage Breast Cancer Patients
GO TO ARTICLE
Copied to clipboard!
accredited arrow-down-editable arrow-down arrow_left arrow-right-blue arrow-right-dark-blue arrow-right-green arrow-right-grey arrow-right-orange arrow-right-white arrow-right-blue arrow-up-orange avatar calendar chevron-down Clicky Media Logo consultant-pathologist-nurse consultant-pathologist cross cross download email exclaimation feedback filter graph-arrow interviews link mdt_icon more_dots nurse-consultant padlock patient-advocate-pathologist patient-consultant patient person pharmacist-nurse play_button play-colour-tmc play-colour Asset 1 podcast printer scenery search share single-doctor social_facebook social_googleplus social_instagram social_linkedin_alt social_linkedin_alt social_pinterest social_youtube shape-star (1) tick-blue tick-orange tick-red tick-white tick time transcript up-arrow webinar
Department Location NEW TMM Corporate Services Icons-07 NEW TMM Corporate Services Icons-08 NEW TMM Corporate Services Icons-09 NEW TMM Corporate Services Icons-10 NEW TMM Corporate Services Icons-11 NEW TMM Corporate Services Icons-12 Salary £ TMM-Corp-Site-Icons-01 TMM-Corp-Site-Icons-02 TMM-Corp-Site-Icons-03 TMM-Corp-Site-Icons-04 TMM-Corp-Site-Icons-05 TMM-Corp-Site-Icons-06 TMM-Corp-Site-Icons-07 TMM-Corp-Site-Icons-08 TMM-Corp-Site-Icons-09 TMM-Corp-Site-Icons-10 TMM-Corp-Site-Icons-11 TMM-Corp-Site-Icons-12 TMM-Corp-Site-Icons-13 TMM-Corp-Site-Icons-14 TMM-Corp-Site-Icons-15 TMM-Corp-Site-Icons-16 TMM-Corp-Site-Icons-17 TMM-Corp-Site-Icons-18 TMM-Corp-Site-Icons-19 TMM-Corp-Site-Icons-20 TMM-Corp-Site-Icons-21 TMM-Corp-Site-Icons-22 TMM-Corp-Site-Icons-23 TMM-Corp-Site-Icons-24 TMM-Corp-Site-Icons-25 TMM-Corp-Site-Icons-26 TMM-Corp-Site-Icons-27 TMM-Corp-Site-Icons-28 TMM-Corp-Site-Icons-29 TMM-Corp-Site-Icons-30 TMM-Corp-Site-Icons-31 TMM-Corp-Site-Icons-32 TMM-Corp-Site-Icons-33 TMM-Corp-Site-Icons-34 TMM-Corp-Site-Icons-35 TMM-Corp-Site-Icons-36 TMM-Corp-Site-Icons-37 TMM-Corp-Site-Icons-38 TMM-Corp-Site-Icons-39 TMM-Corp-Site-Icons-40 TMM-Corp-Site-Icons-41 TMM-Corp-Site-Icons-42 TMM-Corp-Site-Icons-43 TMM-Corp-Site-Icons-44 TMM-Corp-Site-Icons-45 TMM-Corp-Site-Icons-46 TMM-Corp-Site-Icons-47 TMM-Corp-Site-Icons-48 TMM-Corp-Site-Icons-49 TMM-Corp-Site-Icons-50 TMM-Corp-Site-Icons-51 TMM-Corp-Site-Icons-52 TMM-Corp-Site-Icons-53 TMM-Corp-Site-Icons-54 TMM-Corp-Site-Icons-55 TMM-Corp-Site-Icons-56 TMM-Corp-Site-Icons-57 TMM-Corp-Site-Icons-58 TMM-Corp-Site-Icons-59 TMM-Corp-Site-Icons-60 TMM-Corp-Site-Icons-61 TMM-Corp-Site-Icons-62 TMM-Corp-Site-Icons-63 TMM-Corp-Site-Icons-64 TMM-Corp-Site-Icons-65 TMM-Corp-Site-Icons-66 TMM-Corp-Site-Icons-67 TMM-Corp-Site-Icons-68 TMM-Corp-Site-Icons-69 TMM-Corp-Site-Icons-70 TMM-Corp-Site-Icons-71 TMM-Corp-Site-Icons-72